FREEDOM DR: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor or as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
This study has been withdrawn prior to enrollment.
(Study stopped prior to subject enrollment.)
Information provided by:
First received: September 25, 2008
Last updated: January 29, 2013
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Study Status:||This study has been withdrawn prior to enrollment.|
|Study Completion Date:||January 2009|
|Primary Completion Date:||January 2009 (Final data collection date for primary outcome measure)|